Main Article Content
Hydroxymethylglutaryl-CoA Reductase Inhibitors, Coronary Artery Disease, Delivery of Health Care, Integrated, Health Services for the Aged, Aged, Prescription Drugs, Comparative Effectiveness Research, Drug Utilization, Retrospective Studies, United States
Background: High intensity statin therapy (HIST) is the gold standard therapy for decreasing the risk of recurrent atherosclerotic cardiovascular disease (ASCVD); however, little is known about the use of HIST in older adults with ASCVD.
Objectives: The aim of this cross-sequential study was to determine trends in statin intensity in older adults over a 10-year timeframe.
Methods: The study was conducted in an integrated healthcare delivery system. Patients were 76 years or older with validated coronary ASCVD. Data were collected from administrative databases. Statin intensity level was assessed in eligible patients on January 1st and July 1st from January 1, 2007 to December 31, 2016.
Results: Overall, a total of 5,453 patients were included with 2,119 (38.9%) and 3,334 (61.1%) categorized as HIST and Non-HIST, respectively. Included patients had a mean age of 79.8 years and were primarily male and white and had a cardiac intervention. The rate of HIST use increased from 14.5% to 41.3% over the study period (p<0.001 for trend). Conversely, the rates of moderate and low intensity statin use decreased from 61.8% and 9.8% to 41.2% and 4.8%, respectively (both p<0.001 for trend). Similar trends were identified for females and males.
Conclusions: The percentage of patients with ASCVD 76 years and older who received HIST substantially increased from 2007 to 2016. This trend was identified in both females and males. Future comparative effectiveness research should be conducted in this patient population to examine cardiac-related outcomes with HIST and Non-HIST use.
2. Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB Sr, Gibbons R, Greenland P, Lackland DT, Levy D, O'Donnell CJ, Robinson JG, Schwartz JS, Shero ST, Smith SC Jr, Sorlie P, Stone NJ, Wilson PWF. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2935-2959. https://doi.org/10.1016/j.jacc.2013.11.005
3. O'Brien EC, Wu J, Schulte PJ, Christian A, Laskey W, Bhatt DL, Peterson ED, Hernandez AF, Fonarow GC. Statin use, intensity, and 3-year clinical outcomes among older patients with coronary artery disease. Am Heart J. 2016;173:27-34. https://doi.org/10.1016/j.ahj.2015.11.014
4. Ko DT, Mamdani M, Alter DA. Lipid lowering therapy with statins in high-risk elderly patients: the treatment paradox. JAMA. 2004;291(15):1864-1870. https://doi.org/10.1001/jama.291.15.1864
5. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2889-2934. https://doi.org/10.1016/j.jacc.2013.11.002
6. Wilmot KA, Khan A, Krishnan S, Eapen DJ, Sperling L. Statins in the elderly: a patient-focused approach. Clin Cardiol. 2015;38(1):56-61. https://doi.org/10.1002/clc.22338
7. Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670-1681. https://doi.org/10.1016/S0140-6736(10)61350-5
8. Rodriquez F, Maron D, Knowles JW, Virani SS, Lin S, Heidenreich PA. Association between intensity of statin therapy and mortality in patients with atherosclerotic cardiovascular disease. JAMA Cardiol. 2017;2(1):47-54. https://doi.org/10.1001/jamacardio.2016.4052
9. Nanna MG, Navar AM, Wang TY, Mi X, Virani SS, Louie MJ, Lee LV, Goldberg AC, Roger VL, Robinson J, Peterson ED. Statin use and adverse effects among adults > 75 years of age: insights from the patient and provider assessment of lipid management (PALM) registry. J Am Heart Assoc. 2018;7(10):e008546. https://doi.org/10.1161/JAHA.118.008546
10. Musich S, Wang SS, Schwebke K, Slindee L, Waters E, Yeh CS. Underutilization of statin therapy for secondary prevention of cardiovascular disease among older adults. Popul Health Manag. 2019;22(1):74-82. https://doi.org/10.1089/pop.2018.0051
11. Sandhoff BG, Nies LK, Olson KL, Nash JD, Rasmussen JR, Merenich JA. Clinical pharmacy cardiac risk service for managing patients with coronary artery disease in a health maintenance organization. Am J Health Syst Pharm. 2007;64(1):77-84. https://doi.org/10.2146/ajhp060022
12. Merenich JA, Olson KL, Delate T, Rasmussen J, Helling DK, Ward DG; Clinical Pharmacy Cardiac Risk Service Study Group. Mortality reduction benefits of a comprehensive cardiac care program for patients with occlusive coronary artery disease. Pharmacotherapy. 2007;27(10):1370-1378. https://doi.org/10.1592/phco.27.10.1370
13. Todd BA, Lamprecht DG, Stadler SL. Pharmacist prescribing practices in a clinical pharmacy cardiac risk service. Am J Health Syst Pharm. 2016;73(18):1442-1450. https://doi.org/10.2146/ajhp150781
14. Clark DO, Von Korff M, Saunders K, Baluch WM, Simon GE. A chronic disease score with empirically derived weights. Med Care. 1995;33(8):783-795.
15. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, Saunders LD, Beck CA, Feasby TE, Ghali WA. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130-1139.
16. Rosenson RS, Farkouh ME, Mefford M, Bittner V, Brown TM, Taylor B, Monda KL, Zhao H, Dai Y, Muntner P. Trends in use of high-intensity statin therapy after myocardial infarction, 2011 to 2014. J Am Coll Cardiol. 2017;69(22):2696-2706. https://doi.org/10.1016/j.jacc.2017.03.585
17. Lamprecht DG, Shaw PB, King JB, Hogan KN, Olson KL. Trends in high-intensity statin use and low density lipoprotein cholesterol control among patients enrolled in a clinical pharmacy cardiac risk service. J Clin Lipidol. 2018;12(4):999-1007. https://doi.org/10.1016/j.jacl.2018.04.007
18. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ; Coordinating Committee of the National Cholesterol Education Program. Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Arterioscler Thromb Vasc Biol. 2004;24(8):e149-e161. https://doi.org/10.1161/01.ATV.0000133317.49796.0E
19. Salami JA, Warraich H, Valero-Elizondo J, Spatz ES, Desai NR, Rana JS, Virani SS, Blankstein R, Khera A, Blaha MJ, Blumenthal RS, Lloyd-Jones D, Nasir K. National trends in statin use and expenditures in the US adult population from 2002 to 2013: insights from the medical expenditure panel survey. JAMA Cardiol. 2017;2(1):56-65. https://doi.org/10.1001/jamacardio.2016.4700